Group purchasing organizations and purchasing groups, affiliations, and coalitions
We realize that in healthcare, you can’t go it alone. It takes partners and associates coming together in collaboration to achieve efficient, cost-effective care for patients. We also understand the financial and operational pressures faced by today’s hospitals and healthcare systems, because we are a hospital too. Group purchasing organizations (GPOs) and purchasing groups (PGs) help hospitals by shouldering the burden of negotiating the best member pricing and benefits with quality suppliers. At Mayo Clinic Laboratories, we welcome the opportunity to serve members by establishing relationships with their GPOs and PGs to provide member access to our broad esoteric testing menu and services.
Building laboratory value
The financial pressure on hospitals continues. To help, we can support hospital laboratories by evaluating current utilization, capacity, and processes to help reduce waste, find efficiencies, and maximize capabilities for optimal financial performance.
We also offer support in building and expanding laboratory outreach programs. Our experienced, industry-leading outreach consultants offer unparalleled insights and experience to help hospital-based laboratories evolve from cost-centers to revenue generators. Learn more about how we can support laboratories’ optimization and revenue-generation goals.
Driving efficiency through consolidation
Most hospital laboratories find themselves sending tests to an increasing number of commercial and specialty reference laboratories. Managing the complexities of these various relationships increases operational burden, staff workload, and inconsistencies in testing methods and interpretation of results.
Hospitals and health systems can optimize their laboratory testing referrals by leveraging our extensive test menu, which includes advanced diagnostics, cutting-edge technology, and clinically relevant new tests across our full spectrum of medical subspecialties.
“The type of service we provide is really tailored to the needs of the hospital or to the healthcare system. And their patients are no different than the patients that walk through our doors.”
William Morice, M.D., Ph.D., CEO and President of Mayo Clinic Laboratories
Sharing knowledge and empowering staff
We support care teams by providing insights and education as they strive to solve the most complex medical challenges. Our education offerings range from conferences to on-demand programs to webinars — many of which offer CME credit. View our extensive educational offerings.
In addition, hospital and laboratory staff have direct access to Mayo Clinic physicians and scientists, who can help with optimizing test orders and interpreting results. Mayo Clinic Laboratories provides each client with a dedicated team of account, clinical, and laboratory technical professionals.
Prioritizing patient care
With guidance from our practicing physicians, we continuously develop testing algorithms, invest in research, and develop new tests so that patients have access to the best testing available. As a hospital-based reference laboratory, our focus is helping clients prevent overutilization of laboratory testing, drive efficiency through consolidation of send-out testing, and generate hospital revenue by establishing and growing lab outreach programs. And, we provide benefits only available through a connection with a world-class medical institution: access to our Mayo Clinic physicians and consultants, educational offerings, and the most cutting-edge, clinically-based testing available in the market.
News and updates
The latest
Join us Sept. 23–24, 2026, in Rochester, Minnesota, for our annual outreach conference. This year’s event, Leveraging the Laboratory: Bold Thinking. Big Impact., focuses on how innovative approaches and strategic decision-making can drive meaningful results for health system laboratory outreach programs.
This week's research roundup feature: Histoplasma and Blastomyces antigen detection assays are commonly used diagnostic tools. However, a high level of cross-reactivity between these antigens prevents definitive pathogen identification by these assays alone.
Mayo Clinic Laboratories is grateful for the opportunity to serve you and other healthcare professionals around the globe in providing critical answers and actionable insights.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to reflect on key moments from 2023 and to discuss what may lie ahead in 2024.
Endometrial cancer affects thousands annually and ranks as the fourth most common cancer among women in the United States. At the forefront of innovative discoveries in endometrial cancer diagnostics are Mayo Clinic's Department of Laboratory Medicine and Pathology consultants. Sounak Gupta, M.B.B.S., Ph.D., vice chair of Oncology Practice for the Division of Laboratory Genetics and Genomics; Maryam Shahi, M.D., senior consultant for Anatomic Pathology; and Andrea Mariani, M.D., M.S., division chair of Gynecologic Surgery, explore the critical significance of molecular profiling and collaborative efforts driving these innovations, highlighting Mayo Clinic’s revolutionary influence on patient care.
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' GABA-A receptor antibody assay aids diagnosis of this serious but treatable condition.
This week's research roundup feature: R0 resection and radiation therapy have been associated with improved overall survival (OS) in patients with thymic carcinoma (TC). Here, we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, talks with Shannon Bennett, director of regulatory affairs for the Department of Laboratory Medicine and Pathology at Mayo Clinic. They discuss the complex and changing environment of laboratory industry regulations.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., along with the Lab Medicine Rounds podcast team share their experience on starting an educational podcast and reflecting on past episodes.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the U.S. Food and Drug Administration’s (FDA) recent approval of two gene therapies for sickle cell disease.
In her current role as senior manager for global logistics at Mayo Clinic Laboratories, Sarah Mason oversees the coordination of patient sample shipments by working with a network of stakeholders, couriers, carriers, and vendors. Sarah emphasizes the critical nature of safe and timely delivery of more than 38,000 samples each day, highlighting the dynamic challenges in healthcare logistics. Through her work, she finds meaning and purpose in collaborating with diverse teams to bring impactful change to Mayo Clinic operations and its patients.
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients' response to infliximab and adalimumab.
This week's research roundup feature: Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic abnormalities by fluorescence in situ hybridization (FISH) in the clonal plasma cells, obtained either directly from the diagnostic SBP tissue or the corresponding bone marrow examination at the time of diagnosis, is associated with a shorter time to progression (TTP) to MM is unknown. This study evaluated all patients diagnosed with SBP at the Mayo Clinic from January 2012 to July 2022.